Forendo Pharma
Drug discovery and development company with a core competence in tissue specific regulation of sex hormones
Forendo is pioneering the translation of intracrinology science into first-in-class therapeutic solutions in endometriosis and PCOS.
Forendo was acquired by Oragon in 2021.